August 2012
-
Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth… Read more . . .
-
Impax Specialty Pharma has received approval from the FDA to market Zomig zolmitriptan nasal spray for the treatment of migraine in patients 12-17 years of age, the company says. Impax acquired the US rights to… Read more . . .
-
Pulmatrix has issued a series of announcements regarding financing and its trading status on the NASDAQ exchange, a development deal for its PUR0200 inhaled COPD drug, and a new DPI it is developing, using its… Read more . . .
-
A study published online June 11 2015 in the American Journal of Respiratory and Critical Care Medicine showed that asthma patients over 30 years of age who were using inhaled corticosteroids experienced a greater proportion… Read more . . .
-
According to United Therapeutics, the company has received notice that Watson Laboratories, a subsidiary of Allergan, has submitted an Abbreviated New Drug Application (ANDA) for a generic version of United Therapeutics’ Tyvaso treprostinil inhalation solution.… Read more . . .
-
Milestone Pharmaceuticals has raised $17 million in a Series B financing round, the company said. According to the company, it will use the money for Phase 2 clinical development of MSP-2017, its intranasal calcium channel… Read more . . .
-
AmpliPhi BioSciences has announced that a study performed in conjunction with the Royal Brompton Hospital and Imperial College, UK showed that a variety of bacteriophages remain viable against P. aeruginosa after nebulization. Three different commercially… Read more . . .
-
Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two… Read more . . .
-
Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline’s Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in… Read more . . .
-
Adapt Pharma has initiated a rolling NDA submission for intranasal naloxone for the treatment of opioid overdose, the company said. Adapt licensed the intranasal naloxone formulation from Lightlake Therapeutics in December 2014 and received Fast… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland